If this dual inhibition allows for greater efficacy compared to the first generation of mTOR inhibitors without further significant toxic effects, these new agents may open new possibilities in the treatment of tuberous sclerosis [80]. This evidence concerns the gene MTOR and tuberous sclerosis.